



Relationship of Supervision, Side Effects and Complexity to Adherence and Antipsychotic Treatment

Carissa Brewer
BA, Pharm.D. Candidate (2007)
University of California San Diego
Skaggs School of Pharmacy and Pharmaceutical Sciences

Background

- Schizophrenia affects 1% of the population world-wide¹
- Schizophrenia is a debilitating illness that may be effectively managed by the use of antipsychotic medications
- The median medication adherence rate for patients with schizophrenia is around 55%²

Complications due to Medication Nonadherence in Schizophrenia

- Increased Morbidity
 - Change in living situation
 - Independent → Supervised living → Hospital
 - Increased hospitalization
 - 2.4 times as likely in nonadherent patients¹
 - Increased cost
 - In 1999 the National Institutes of Health ranked schizophrenia as the 5th most costly chronic illness in the United States²
- Increased Mortality
 - Under debate

Risk Factors for Antipsychotic Nonadherence

- Patient related risk factors
 - Poor insight
 - Negative attitude toward or subjective response to medication
 - Previous nonadherence
 - Shorter duration of illness
 - Current or past history of substance abuse
 - Severity of psychotic symptoms (?)
- Medication related risk factors
 - Higher antipsychotic dose (?)
 - Medication complexity
 - Antipsychotic type
- Environment related risk factors
 - Poor alliance with therapist or clinician or less outpatient contact
 - Poor family involvement
 - Instability of living arrangements

Objective

- To determine whether adherence to antipsychotic treatment was affected by:
 - Availability of medication supervision
 - Medication side effect burden
 - Complexity of the medication regimen

Study Participants

- Data extraction collected as part of a larger ongoing study
 - Study participants
 - Older outpatients with schizophrenia or schizoaffective disorder
 - On maintenance therapy with antipsychotic treatment
 - Study focus
 - Identify risk factors associated with medication nonadherence
 - Determine effectiveness of multimodal intervention to improve medication adherence and patient outcomes
 - Baseline data used in this analysis

Medication Possession Ratio (MPR) and Medication Adherence

- 12 months of pharmacy refill records
- Calculation
 - $MPR = \frac{\text{(Number of Days Drug was Available)}}{\text{(Total time)}}^1$
- Adherence Assignment
 - Adherent
 - $MPR = 0.80 - 1.10$
 - Nonadherent
 - $MPR < 0.80$ or > 1.10
 - Multiple antipsychotics
 - Considered to be nonadherent if found to be nonadherent to a single antipsychotic medication

Available Medication Supervision

- None
 - Independently responsible for that administration of his or her medications
- Some or complete
 - Some
 - Responsible for medication administration but receives some form of medication administration assistance such as reminders, cues, to obtain refills, organization of adherence aids or dispensing of medications from a care provider
 - Complete
 - All aspects of medication consumption are managed by a third party

Assessment of Side Effects

- Udvalg Kliniske Undersogelser Scale (UKU):
 - Monitors the presence and severity of non-neurological side effects associated with antipsychotic medication¹
- Abnormal Involuntary Movement Scale (AIMS):
 - 12-item instrument that assesses abnormal involuntary movements²
- Barnes Akathisia Scale (BAS):
 - 4-item scale that assesses drug-induced akathisia
 - Global severity rating on a 6-point scale (0 = absent, 5 = severe)³
- Simpson-Angus Extrapyrarnidal Scale (SAES):
 - Instrument used to measure drug-induced parkinsonism⁴
- Positive and Negative Syndrome Scale (PANSS):
 - 30-item rating instrument that evaluates positive, negative, and other symptoms in patients with schizophrenia⁵

Assessment of Medication Complexity


- Medication Complexity Index
 - Number of administration times per day for all scheduled medications
- Antipsychotic Polypharmacy
 - Antipsychotic type of treatment
 - Atypical only vs Typical only vs Atypical + Typical
 - Monotherapy vs polytherapy
- Number of medications
 - Antipsychotics
 - Other psychotropics
 - Nonpsychotropics
 - All medications

Demographics


	Adherent (n = 89)	Nonadherent (n = 28)	Total Subjects (n = 117)
Age, years Mean, (SD)	51.8 (6.7)	52.0 (7.1)	51.8 (6.7)
Male Gender n, (%)	58 (65)	19 (68)	77 (66)
Ethnicity, Caucasian n, (%)	68 (76)	22 (79)	90 (77)
Diagnosis, Schizophrenia n, (%)	64 (72)	20 (71)	84 (72)
PANSS total score Mean, (SD)	55.0 (13.7)	50.9 (9.7)	54.0 (13.0)

Medication Oversight


$\chi^2 = 3.521, df = 1, p = .0047$




Side Effects




Medication Use



Medication Complexity and Antipsychotic Polypharmacy




Adherence Type



of Antipsychotics

Antipsychotic Type

Overall: $\chi^2 = 7.687$, $df = 2$, $p = .021$



Discussion of Limitations

- Patient population
 - Predominantly older white males
 - Small population size
 - Data collection
 - Pharmacy refill records brought in by patient
 - Accurate recollection of pharmacies used
 - Completion of numerous release forms if applicable
- Medication possession ratio calculation
 - Does not take into account lost medication for patients who appear to be excess fillers and thus non-compliant
 - Although it is a good estimate it is not 100% representative of patient compliance
 - Extra medication accrued from hospitalizations
- Analysis of antipsychotic polypharmacy
 - Did not exclude as needed medications

Conclusion

- Preliminary analysis of our data suggests:
 - Medication oversight may increase medication adherence
 - Antipsychotic polypharmacy may positively impact medication adherence
 - An antipsychotic regimen including both typical and atypical antipsychotic medications may increase adherence over single typical or atypical antipsychotic therapy
 - Medication side effect burden and complexity of the medication regimen do not have a significant effect on medication adherence

Acknowledgements

■ Authors:

- Sigfrido Urtecho
- Lisa DeVuyst
- Jonathan P. Lacro, PharmD, BCPS, BCPP

■ Affiliates:

- University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
- Veterans Medical Research Foundation
- VA San Diego Healthcare System and University of California, San Diego, School of Medicine – Department of Psychiatry